With great interest, I read the interesting paper entitled: Techniques to Treat Slow-Flow/No-Reflow During Primary Percutaneous Coronary Intervention [1] . The authors clearly demonstrate the benefit of distal administration of active drugs through an export catheter as the best treatment option with a much higher success rate for the treatment of no-reflow. Unfortunately, the authors did not cite important previous published works in this regard and did not give any credit to authors who described this method with great success in the past. The first-in-man experience of giving very high doses of adenosine distally was published by our group successfully treating a patient with resistant no-reflow after stenting in 2008 [2] . Furthermore, Wilson et al. [3] were the first to successfully treat resistant no-reflow by giving distal administration of drugs through a Clearway catheter (Atrium Medical, Hudson, NH) into coronaries (not referenced in this paper) before much later time of the reported case series 7 years later in 2018 using a perforated balloon catheter [4] . Clearway is a rapid exchange balloon catheter used for distal drug delivery. Finally, the successful first-in-man reported case of using distal high-dose adenosine delivery using an export catheter was reported in 2022 for this purpose [5] which was also not mentioned in this manuscript.